These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36165729)

  • 1. STING Agonists in Head and Neck Squamous Cell Carcinoma.
    Wallington DG; Contessa JN; Hayman TJ
    Cancer J; 2022 Sep-Oct 01; 28(5):401-406. PubMed ID: 36165729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
    Ye G; Zhang J; Zhang C
    Aging (Albany NY); 2021 Aug; 13(16):20793-20807. PubMed ID: 34459788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma.
    Xie G; Shan L; Yang C; Liu Y; Pang X; Teng S; Wu TC; Gu X
    Sci Rep; 2023 Oct; 13(1):18476. PubMed ID: 37898690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
    Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
    Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sono-Driven STING Activation using Semiconducting Polymeric Nanoagonists for Precision Sono-Immunotherapy of Head and Neck Squamous Cell Carcinoma.
    Jiang J; Zhang M; Lyu T; Chen L; Wu M; Li R; Li H; Wang X; Jiang X; Zhen X
    Adv Mater; 2023 Jul; 35(30):e2300854. PubMed ID: 37119091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
    Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
    Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
    Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
    Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
    Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
    Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING enhances cell death through regulation of reactive oxygen species and DNA damage.
    Hayman TJ; Baro M; MacNeil T; Phoomak C; Aung TN; Cui W; Leach K; Iyer R; Challa S; Sandoval-Schaefer T; Burtness BA; Rimm DL; Contessa JN
    Nat Commun; 2021 Apr; 12(1):2327. PubMed ID: 33875663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cGAS-STING responses are dampened in high-risk HPV type 16 positive head and neck squamous cell carcinoma cells.
    Shaikh MH; Bortnik V; McMillan NA; Idris A
    Microb Pathog; 2019 Jul; 132():162-165. PubMed ID: 31054871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
    Harabuchi S; Kosaka A; Yajima Y; Nagata M; Hayashi R; Kumai T; Ohara K; Nagato T; Oikawa K; Ohara M; Harabuchi Y; Ohkuri T; Kobayashi H
    Biochem Biophys Res Commun; 2020 Feb; 522(2):408-414. PubMed ID: 31771883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
    Zhu C; Li J; Yao M; Fang C
    BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T; Komatsuda H; Minami Y; Harabuchi Y
    ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.